Systematic (IUPAC) name
Clinical data
Pregnancy cat.
  • ?
Legal status
Routes Oral
Pharmacokinetic data
Bioavailability ?
Metabolism Hepatic
Excretion Renal
CAS number  YesY
ATC code None
ChemSpider  YesY
Chemical data
Formula C17H16N2OS 
Mol. mass 296.387 g/mol

Bentazepam[1] (also known as Thiadipone) is a thienodiazepine which is a benzodiazepine analog.[2] It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Peak plasma rates are achieved in around two and a half hours after oral administration.[3] The elimination half-life is between approximately 2 – 4 hours.[2][4] Bentazepam is effective as an anxiolytic. A severe benzodiazepine overdose with bentazepam may result in coma and respiratory failure.[5] Adverse effects include dry mouth, somnolence, asthenia, dyspepsia, constipation, nausea.[6] and Drug-induced lymphocytic colitis has been associated with bentazepam.[7][8] Severe liver damage and hepatitis has also been associated with bentazepam.[9][10][11] Whilst liver failure from bentazepam is considered to be rare, liver function monitoring has been recommended for all patients taking bentazepam.[12]

It is marketed in Spain as Tiadipona.

See also


  1. ^ DE Patent 2005276
  2. ^ a b Gonzalez López, F; Mariño, EL; Dominguez-Gil, A (1986). "Pharmacokinetics of tiadipone: a new anxiolytic". International journal of clinical pharmacology, therapy, and toxicology 24 (9): 482–4.  
  3. ^ Mariño, EL; Fernandez Lastra, C; Gonzalez Lopez, F; Dominguez-Gil, A; Garcia Santalla, JL; Vorca, G; Izquierdo, JA; Ledesma-Jimeno, A (1987). "Parametrization by non-linear regression and bayesian estimation of bentazepam in a multiple dosage regimen in humans". International journal of clinical pharmacology, therapy, and toxicology 25 (11): 627–32.  
  4. ^ Colino, CI; Lastra, CF; López, FG; Ledesma, A; Mariño, EL (1991). "Open-loop feedback control of serum bentazepam concentrations and Bayesian estimation in multiple dosage regimens in patients.". International journal of clinical pharmacology, therapy, and toxicology 29 (11): 457–62.  
  5. ^ Rivas López, FA; López Soriano, F; Mendoza Cerezo, A; Jiménez Ferré, J; Azurmendi Rodríguez, JI; De La Rubia Nieto (1989). "Mixed benzodiazepine poisoning and reversal with flumazenil (Ro 15-1788)". Revista espanola de anestesiologia y reanimacion 36 (1): 48–50.  
  6. ^ Honorato, J; Rubio, A; Tristán, C; Otero, FJ; Garrido, J (1990). "A pharmacovigilance study with bentazepam in a sample of 1046 psychiatric outpatients". Revista de medicina de la Universidad de Navarra 34 (2): 80–8.  
  7. ^ Fernández-Bañares, F; Salas, A; Esteve, M; Espinós, J; Forné, M; Viver, JM (2003). "Collagenous and lymphocytic colitis. evaluation of clinical and histological features, response to treatment, and long-term follow-up.". The American journal of gastroenterology 98 (2): 340–7.  
  8. ^ De-La-Serna, C; Gil-Grande, LA; Sanromán, AL; Gonzalez, M; Ruiz-Del-Arbol, L; Garcia Plaza, A (1997). "Bentazepam-induced hepatic bridging necrosis.". Journal of Clinical Gastroenterology 25 (4): 710–1.  
  9. ^ Andrade, RJ; Lucena, MI; Kaplowitz, N; García-Muņoz, B; Borraz, Y; Pachkoria, K; García-Cortés, M; Fernández, MC et al. (2006). "Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry". Hepatology (Baltimore, Md.) 44 (6): 1581–8.  
  10. ^ Tuca, Albert (2003). "Utilidad clinica del acetato de megestrol para la ganancia de peso en los enfermos con neoplasia y caquexia". Medicina Clinica (in Spanish) 120 (17): 678.  
  11. ^ Andrade, RJ; Lucena, MI; Alcantara, R; Fraile, JM (1994). "Bentazepam-associated chronic liver disease.". Lancet 343 (8901): 860.  
  12. ^ Andrade, RJ; Lucena, MI; Aguilar, J; Lazo, MD; Camargo, R; Moreno, P; García-Escaño, MD; Marquez, A et al. (2000). "Chronic liver injury related to use of bentazepam: an unusual instance of benzodiazepine hepatotoxicity". Digestive diseases and sciences 45 (7): 1400–4.